Effect of pentoxifylline on decreased in vitro mononuclear leucocyte chemotaxis in vascular and polysystemic autoimmune diseases
Related Experiment Videos
Z Szekanecz1, G Szabó, I Sonkoly
13rd Department of Medicine, University Medical School of Debrecen, Hungary.
Abstract:
Impaired mononuclear leucocyte (MNL) motility can be found both in vascular and autoimmune diseases. Pentoxifylline (PTX) has a well-known therapeutic effect in vascular diseases, which is based on the rearrangement of blood cell cytoskeleton and thus increased microcirculatory flow. Most data on PTX concern red blood cells and granulocytes so now the effect of PTX on previously decreased MNL migration and chemotaxis was investigated in vitro. The results of MNL chemotaxis studies described here suggest that this drug enhances impaired MNL motility in obliterative atherosclerosis and systemic lupus erythematosus and thus may also be introduced in the treatment of certain polysystemic autoimmune diseases with decreased in vitro MNL chemotaxis.
Insights
Pentoxifylline (PTX) improves impaired mononuclear leucocyte (MNL) motility in conditions like atherosclerosis. This suggests PTX could treat autoimmune diseases by enhancing MNL function.
Area of Science:
- Immunology
- Pharmacology
Background:
- Mononuclear leucocyte (MNL) motility is crucial for immune response and is impaired in vascular and autoimmune diseases.
- Pentoxifylline (PTX) is known to improve microcirculatory flow by affecting blood cell cytoskeleton, primarily studied in red blood cells and granulocytes.
Purpose of the Study:
- To investigate the in vitro effect of Pentoxifylline (PTX) on previously decreased mononuclear leucocyte (MNL) migration and chemotaxis.
- To explore the potential of PTX in treating autoimmune diseases characterized by impaired MNL function.
Main Methods:
- In vitro studies of mononuclear leucocyte (MNL) chemotaxis.
- Assessment of PTX's effect on MNL migration and motility.
Main Results:
- Pentoxifylline (PTX) was found to enhance the impaired motility of mononuclear leucocytes (MNLs).
- The drug demonstrated a positive effect on MNL chemotaxis in models of obliterative atherosclerosis and systemic lupus erythematosus.
Conclusions:
- Pentoxifylline (PTX) enhances impaired mononuclear leucocyte (MNL) motility and chemotaxis in vitro.
- PTX may be a potential therapeutic agent for systemic autoimmune diseases with decreased MNL chemotaxis.